Systemic and hepatosplanchnic hemodynamic and metabolic effects of the PARP inhibitor PJ34 during hyperdynamic porcine endotoxemia

Shock

Volumn 19, Issue 5, 2003, Pages 415-421

  Iványi, Zsolt ^a   Hauser, Balázs ^a   Pittner, Antje ^a   Asfar, Pierre ^a   Vassilev, Damian ^a   Nalos, Marek ^a   Altherr, Jürgen ^a   Brückner, Uwe Bernd ^b   Szabó, Csaba ^c,d   Radermacher, Peter ^a,b   Fröba, Gebhard ^a  

^a Institut Für Anästhesiologische Pathophysiologie Und VerfahrensentwicklungUniversitätsklinikum   (Germany)

^b UNIVERSITY HOSPITAL ULM   (Germany)

^c INOTEK CORPORATION   (United States)

^d RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

Blood flow; Gut; Ileal mucosal arterial PCO2 gap; Lactate pyruvate ratio; Liver; Metabolism; Oxygen

Indexed keywords

LACTIC ACID; LIPOPOLYSACCHARIDE; N (5,6 DIHYDRO 6 OXO 2 PHENANTHRIDINYL) 2 DIMETHYLAMINOACETAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ARTIFICIAL VENTILATION; CARBON DIOXIDE TENSION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; ENDOTOXEMIA; ENZYME INHIBITION; FLUID RESUSCITATION; HEART OUTPUT; HEART STROKE VOLUME; HEMODYNAMICS; ILEUM MUCOSA; INOTROPISM; LIVER METABOLISM; MEAN ARTERIAL PRESSURE; NONHUMAN; SHOCK; SPLANCHNIC BLOOD FLOW; SYSTEMIC VASCULAR RESISTANCE;

ACID-BASE EQUILIBRIUM; ANIMALS; DISEASE MODELS, ANIMAL; ENDOTOXEMIA; ENZYME INHIBITORS; FEMALE; HEMODYNAMIC PHENOMENA; LACTATES; LIPOPOLYSACCHARIDES; LIVER; LIVER CIRCULATION; MALE; OXYGEN; OXYGEN CONSUMPTION; PHENANTHRENES; POLY(ADP-RIBOSE) POLYMERASES; REFERENCE VALUES; SPLANCHNIC CIRCULATION; SWINE;

EID: 1242303935     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.shk.0000048904.46342.22     Document Type: Article

References (35)

1. Smith S: The world according to PARP. Trends Biochem Sci 26:174-179, 2001.
2. Szabó C: Role of poly(ADP-ribose) synthetase activation in the suppression of cellular energetics in response to nitric oxide and peroxynitrite. Biochem Soc Trans 25:919-924, 1997.
3. Szabó C: The role of poly(ADP-ribose) synthetase activation. In Evans TM, Fink MP (eds): Mechanisms of Organ Dysfunction in Critical Illness. Update in Intensive Care and Emergency Medicine 38. Berlin, Heidelberg: Springer Verlag, 2002, pp 40-51.
4. Thiemermann C, Bowes J, Myint FP, Vane JR: Inhibition of the activity of poly(ADP ribose) synthetase reduces ischemia-reperfusion injury in the heart and skeletal muscle. Proc Natl Acad Soc USA 94:679-683, 1997.
5. Zingarelli B, Cuzzocrea S, Zsengeller Z, Salzman AL, Szabo C: Protection against myocardial ischemia and reperfusion injury by 3-aminobenzamide, an inhibitor of poly(ADP-ribose)symhetase. Cadiovasc Res 36:205-215, 1997.
6. Bowes J, Ruetten H, Martorana PA, Stockhausen H, Thiemermann C: Reduction of myocardial reperfusion injury by an inhibitor of poly(ADP-ribose) synthetase in the pig. Eur J Pharmacol 23:143-150, 1998.
7. Cuzzocrea S, Zingarelli B, Costantino G, Szabo A, Salzman AL, Caputi AP, Szabó C: Beneficial effects of 3-aminobenzamide, an inhibitor of poly(ADP-ribose) synthetase in a rat model of splanchnic artery occlusion and reperfusion. Br J Pharmacol 121:1065-1074, 1997.
8. Liaudet L, Szabó A, Soriano FG, Zingarelli B, Szabó C, Salzman AL: Poly-(ADP-ribose) synthetase mediates intestinal mucosal barrier dysfunction after mesenteric ischemia. Shock 14:134-141, 2000.
9. Liaudet L, Pacher P, Mabley JG, Virág L, Soriano FG, Haskó G, Szabó C: Activation of poly(ADP-ribose) polymerase-1 is a central mechanism of lipopolysaccharide-induced acute lung inflammation. Am J Respir Crit Care Med 165:372-377, 2002.
10. Szabó A, Hake P, Salzman AL, Szabó C: 3-Aminobenzamide, an inhibitor of poly(ADP-ribose) synthetase, improves hemodynamics and prolongs survival in a porcine model of hemorrhagic shock. Shock 10:347-353, 1998.
11. McDonald MC, Filipe HM, Thiemermann C: Effects of inhibitors of the activity of poly(ADP-ribose) synthetase on the organ injury and dysfunction caused by haemorrhagic shock. Br J Pharmacol 128:1339-1345, 1999.
12. McDonald MC, Mota-Filipe H, Wright JA, Abdelkarim M, Threadgill MD, Thompson AS, Thiemermann C: Effects of 5-aminoisoquinolone, a water-soluble, potent inhibitor of the activity of poly(ADP-ribose) polymerase on the organ injury and dysfunction caused by haemorrhagic shock. Br J Pharmacol 130:843-850, 2000.
13. Soriano FG, Liaudet L, Szabó E, Virág L, Mabley JG, Pacher P, Szabó C: Resistance against acute septic peritonitis in poly(ADP-ribose) polymerase deficient mice. Shock 17:286-292, 2002.
14. Goldfarb RD, Marton A, Szabó E, Virag L, Salzman AL, Glock D, McCarthy R, Parillo JE, Szabó C: Protective effect of a novel, potent inhibitor of poly(ADP-ribose) synthetase in a porcine model of severe bacterial sepsis. Crit Care Med 30:974-980, 2002.
15. Faro R, Toyoda Y, McCully JD, Jagtap P, Szabó E, Virág L, Bianchi C, Levitsky S, Szabó C, Sellke RV: Myocardial protection by PJ34, a novel potent poly(ADP-ribose) synthetase inhibitor. Ann Thorac Surg 73:575-581, 2002.
16. Fink MP, Heard SO: Laboratory models of sepsis and septic shock. J Surg Res 49:186-196, 1990.
17. 2-exchange and energy metabolism during hyperdynamic porcine endotoxemia. Intensive Care Med 27:586-592, 2001.
18. Wray GM, Hinds CJ, Thiemermann C: Effects of inhibitors of poly(ADP-ribose) synthetase activity hypotension and multiple organ dysfunction caused by endotoxin. Shock 10:13-19, 1998.
19. Watts JA, Grattan RM, Whitlow BS, Kline JA: Activation of poly(ADP-ribose) polymerase in severe hemorrhagic shock and resuscitation. Am J Physiol 281:G498-G506, 2001.
20. Jagtap P, Soriano FG, Vírag L, Liaudet L, Mabley J, Szabó E, Haskó G, Marton A, Lorigados BC, Gallyas F, Sümegi B, Hoyt DG, Baloglu E, VanDuzer J, Salzman AL, Southan GJ, Szabö C: Novel phenanthridinone inhibitors of poly(ADP-ribose) synthetase: potent cytoprotective and anti-shock agents. Crit Care Med 30:1071-1082, 2002.
21. Abdelkarim GE, Gertz K, Harms C, Katchanov J, Dimagl U, Szabó C, Endres M: Protective effects of PJ34, a novel, potent inhibitor of poly(ADP-ribose) polymerase (PARP) in in vitro and in vivo models of stroke. Int J Mol Med 7:255-260, 2001.
22. Soriano FG, Pacher P, Mabley L, Liaudet L, Szabo C: Rapid reversal of the diabetic endothelial dysfunction by pharmacological inhibition of poly(ADP-ribose) polymerase. Circ Res 89:684-691, 2001.
23. Asfar P, Nalos M, Pittner A, Theisen M, Ichai C, Ploner F, Georgieff M, Ince C, Brückner UB, Leverve XM, Radermacher P, Fröba G: Adenosine-triphosphate-magnesium dichloride during hyperdynamic porcine endotoxemia: effects on hepato-splanchnic oxygen exchange and metabolism. Crit Care Med 30:1826-1833, 2002.
24. Hassoun HT, Kone BC, Mercer DW, Moody FG, Weisbrodt NW, Moore FA: Post-injury multiple organ failure: the role of the gut. Shock 15:1-10, 2001.
25. 2-gap is associated with impaired villous microcirculation in endotoxic pigs. Intensive Care Med 27:757-766, 2001.
26. Szabó A, Salzman AL, Szabó C: Poly(ADP-ribose) synthetase activation mediates pulmonary microvascular and intestinal mucosal dysfunction in endotoxin shock. Life Sci 63:2133-2199, 1998.
27. Cuzzocrea S, Zingarelli B, Costantino G, Sottile A, Teti D, Caputi AP: Protective effect of poly(ADP-ribose) synthetase inhibition on multiple organ failure after zymosan-induced peritonitis in the rat. Crit Care Med 27:1517-1523, 1999.
28. Taner AS, Cinel I, Ozer L, Onde U, Taner D, Koksoy C: Poly(ADP-ribose) synthetase inhibition reduces bacterial translocation in rats after endotoxin challenge. Shock 16:159-162, 2001.
29. Mabley JG, Jagtap P, Perretti M, Getting SJ, Salzman AL, Virag L, Szabó E, Soriano FG, Liaudet L, Abdelkarim GE, Hasko G, Marton A, Southan GJ, Szabó C: Anti-inflammatory effects of a novel, potent inhibitor of poly(ADP-ribose) polymerase. Inflamm Res 50:561-569, 2001.
30. Lichtwarck-Aschoff M, Beale R, Pfeiffer UJ: Central venous pressure, pulmonary artery occlusion pressure, intrathoracic blood volume, and right ventricular end-diastolic volume as predictors of cardiac preload. J Crit Care 11:180-188, 1996.
31. Pacher P, Liaudet L, Soriano FG, Mabley JG, Szabo E, Szabo C: The role of poly(ADP-ribose) polymerase activation in the development of myocardial and endothelial dysfunction in diabetes. Diabetes 51:514-521, 2002.
32. Lobo SM, Dimopoulos G, DeBacker D, Sun Q, Tu Z, Preiser JC, Szabó C, Vincent JL: Effects of a novel poly(ADP-ribose) synthetase inhibitor on serum and luminal gut lactate release in a rabbit model of endotoxic shock [abstract]. Intensive Care Med 27(Suppl 2):S137, 2001.
33. Salzman AL, Wang H, Wollen PS, VanderMeer TJ, Compton CC, Denenberg AG, Fink MP: Endotoxin-induced ileal mucosal hyperpermeability in pigs: role of tissue acidosis. Am J Physiol 266:G633-G646, 1994.
34. Ince C, Sinaasappel M: Microcirculatory oxygenation and shunting in sepsis and shock. Crit Care Med 27:1369-1377, 1999.
35. Yamamoto K, Tsukidate K, Farber JL: Differing effects of the inhibition of poly(ADP-ribose) polymerase on the course of oxidative cell injury in hepatocytes and fibroblasts. Biochem Pharmacol 46:483-491, 1993.